Tesamorelin Long-Term Safety Study in HIV Patients Terminated Early

Individuals living with HIV often experience abdominal lipohypertrophy, a condition characterized by excess visceral fat accumulation, which can lead to metabolic complications and impact quality of life. Tesamorelin (EGRIFTA®) is approved to reduce this excess abdominal fat. However, long-term safety data, particularly regarding potential risks like malignancies and Type 2 Diabetes Mellitus, has been a critical gap in understanding its full clinical profile. This Phase 4 observational study aimed to assess the long-term safety of Tesamorelin exposure over a 10-year period in HIV-infected subjects.

This Phase 4 observational study, designed to track 391 subjects over 10 years, was unfortunately terminated early in 2018, approximately 5.5 years into its intended duration. > Consequently, the primary outcome regarding the time to development of malignancies with Tesamorelin exposure over a 10-year period could not be assessed. Similarly, secondary outcomes such as the long-term incidence of Type 2 Diabetes Mellitus, diabetic retinopathy, hepatic and renal function changes, or major adverse cardiovascular events in the Tesamorelin group versus control remain unquantified. The early termination means no definitive conclusions about the long-term safety profile of Tesamorelin could be drawn from this specific study, leaving the 10-year safety profile largely uncharacterized.